Haiti

Resilience System


Second Chinese vaccine approved by WHO

Primary tabs

Second Chinese vaccine approved by WHO

The World Health Organization (WHO) said on Tuesday it has approved a COVID-19 vaccine made by Sinovac Biotech (SVA.O) for emergency use listing, paving the way for a second Chinese shot to be used in poor countries.

A WHO emergency listing is a signal to national regulators of a product's safety and efficacy and will allow the Sinovac shot to be included in COVAX, the global programme providing vaccines mainly for poor countries, which faces major supply problems due to curbs on Indian exports. read more

The WHO's independent panel of experts said in a statement it recommended Sinovac's vaccine for adults over 18. There was no upper age limit as data suggested it is likely to have a protective effect in older people.

The WHO's technical advisory group, which began meeting on May 5, made the decision after reviewing the latest clinical data on the Sinovac vaccine's safety and efficacy as well as the company's manufacturing practices. ...

Branded CoronaVac in some regions, it is the eighth vaccine to win such a WHO listing to combat COVID-19 and the second developed by a Chinese company, after the May 7 approval of a shot developed by state-backed Sinopharm. read more

While a third Chinese vaccine, produced by CanSino Biologics (6185.HK), has submitted clinical trial data, no WHO review has been scheduled.

The endorsement is a big boost for Sinovac's vaccine after data in clinical trials showed a wide range of efficacy rates.

The WHO said results showed it prevented symptomatic disease in 51% of those vaccinated and prevented severe COVID-19 and hospitalisation in 100% of the studied population.

The WHO's separate Strategic Advisory Group of Experts (SAGE) had said previously that vaccine efficacy in multi-country Phase III clinical trials ranged from 51% to 84%.

Indonesia said on May 12 that its study of 120,000 healthcare workers who had received the vaccine found it was 94% effective at preventing symptomatic disease. read more  ...

 

 

 

 

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 
Groups this Group Post belongs to: 
- Private group -
Workflow history
Revision ID Field name Date Old state New state name By Comment Operations
No state No state
howdy folks
Page loaded in 0.449 seconds.